Mechanisms of radionuclide therapy for tumors and research advances in gliomas

doi:10.3760/cma.j.cn371439-20250530-00123

Abstract

Abstract:

Glioma， particularly glioblastoma， is a type of highly malignant central nervous system tumors with extremely poor prognoses. In recent years， radionuclides have demonstrated unique advantages in the diagnosis and treatment of gliomas. Radionuclide therapy enables precise tumor cell eradication through the emission of radioactive particles， and further achieves precise radiotherapy by crossing the blood-brain barrier through diverse delivery systems. However， at present， there is a lack of research on precise targeting of glioma stem cells and the combined strategy of radiotherapy and immunotherapy. As research continues to advance， radionuclide therapy holds promise for breaking through the existing therapeutic limitations and offering new directions for the comprehensive treatment of gliomas.

Key words: Radioisotopes, Glioma, Receptor-targeted radionuclide therapy

Liao Zhipeng, He Yonglin, Du Aichao, Pan Yawen. Mechanisms of radionuclide therapy for tumors and research advances in gliomas[J]. Journal of International Oncology, 2025, 52(11): 720-725.

References 51

[1]	Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016-2020[J]. Neuro Oncol, 2023, 25(12 Suppl 2): iv1-iv99. DOI: 10.1093/neuonc/noad149.
[2]	Miller KD, Ostrom QT, Kruchko C, et al. Brain and other central nervous system tumor statistics, 2021[J]. CA Cancer J Clin, 2021, 71(5): 381-406. DOI: 10.3322/caac.21693.
[3]	Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
[4]	Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review[J]. Jama, 2023, 329(7): 574-587. DOI: 10.1001/jama.2023.0023. pmid: 36809318
[5]	Price M, Ballard C, Benedetti J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2017-2021[J]. Neuro Oncol, 2024, 26(Supplement_6): vi1-vi85. DOI: 10.1093/neuonc/noae145.
[6]	杨学军, 江涛, 陈忠平, 等. 世界卫生组织中枢神经系统肿瘤分类的演变: 1979—2021年[J]. 中国现代神经疾病杂志, 2021, 21(9): 710-724. DOI: 10.3969/j.issn.1672-6731.2021.09.002.
[7]	南阳, 钟跃. 恶性胶质瘤的分子靶向治疗[J]. 国际肿瘤学杂志, 2017, 44(9): 689-692. DOI: 10.3760/cma.j.issn.1673-422X.2017.09.012.
[8]	Xu S, Luo C, Chen D, et al. circMMD reduction following tumor treating fields inhibits glioblastoma progression through FUBP1/FIR/DVL1 and miR-15b-5p/FZD6 signaling[J]. J Exp Clin Cancer Res, 2023, 42(1): 64. DOI: 10.1186/s13046-023-02642-z. pmid: 36932454
[9]	Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy [J]. Cancer Immunol Immunother, 2020, 69(7): 1191-1204. DOI: 10.1007/s00262-020-02534-7. pmid: 32144446
[10]	Ballo MT, Conlon P, Lavy-Shahaf G, et al. Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis[J]. J Neurooncol, 2023, 164(1): 1-9. DOI: 10.1007/s11060-023-04348-w.
[11]	Bodei L, Herrmann K, Schöder H, et al. Radiotheranostics in oncology: current challenges and emerging opportunities[J]. Nat Rev Clin Oncol, 2022, 19(8): 534-550. DOI: 10.1038/s41571-022-00652-y. pmid: 35725926
[12]	Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible[J]. CA Cancer J Clin, 2023, 73(3): 255-274. DOI: 10.3322/caac.21768.
[13]	Nelson BJB, Andersson JD, Wuest F. Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications[J]. Pharmaceutics, 2020, 13(1): 49. DOI: 10.3390/pharmaceutics13010049.
[14]	Pomykala KL, Hadaschik BA, Sartor O, et al. Next generation radiotheranostics promoting precision medicine[J]. Ann Oncol, 2023, 34(6): 507-519. DOI: 10.1016/j.annonc.2023.03.001. pmid: 36924989
[15]	Song H, Sgouros G. Alpha and beta radiation for theragnostics[J]. PET Clin, 2024, 19(3): 307-323. DOI: 10.1016/j.cpet.2024.03.006. pmid: 38688775
[16]	肖楠, 孙鹏飞. 氧化应激在胶质瘤放化疗敏感性中的研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 357-361. DOI: 10.3760/cma.j.cn371439-20220309-00068.
[17]	Eychenne R, Chérel M, Haddad F, et al. Overview of the most promising radionuclides for targeted alpha therapy: the “hopeful eight”[J]. Pharmaceutics, 2021, 13(6): 906. DOI: 10.3390/pharmaceutics13060906.
[18]	Howell RW. Advancements in the use of auger electrons in science and medicine during the period 2015-2019[J]. Int J Radiat Biol, 2023, 99(1): 2-27. DOI: 10.1080/09553002.2020.1831706.
[19]	Filippi L, Urso L, Evangelista L. PARP-targeted radiotheranostics with auger electrons: an updated overview[J]. Curr Issues Mol Biol, 2024, 46(4): 3039-3049. DOI: 10.3390/cimb46040190. pmid: 38666920
[20]	Nelson BJB, Krol V, Bansal A, et al. Aspects and prospects of preclinical theranostic radiopharmaceutical development[J]. Theranostics, 2024, 14(17): 6446-6470. DOI: 10.7150/thno.100339. pmid: 39479448
[21]	Schuchardt C, Zhang J, Kulkarni HR, et al. Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution, and dosimetry[J]. J Nucl Med, 2022, 63(8): 1199-1207. DOI: 10.2967/jnumed.121.262713.
[22]	Morris MJ, Castellano D, Herrmann K, et al. ¹⁷⁷Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial[J]. Lancet, 2024, 404(10459): 1227-1239. DOI: 10.1016/S0140-6736(24)01653-2. pmid: 39293462
[23]	Fortunati E, Argalia G, Zanoni L, et al. New PET radiotracers for the imaging of neuroendocrine neoplasms[J]. Curr Treat Options Oncol, 2022, 23(5): 703-720. DOI: 10.1007/s11864-022-00967-z.
[24]	Tang H, Cai L, He X, et al. Radiation-induced bystander effect and its clinical implications[J]. Front Oncol, 2023, 13: 1124412. DOI: 10.3389/fonc.2023.1124412.
[25]	Medler TR, Blair TC, Crittenden MR, et al. Defining immunogenic and radioimmunogenic tumors[J]. Front Oncol, 2021, 11: 667075. DOI: 10.3389/fonc.2021.667075.
[26]	Saini S, Gurung P. A comprehensive review of sensors of radiation-induced damage, radiation-induced proximal events, and cell death[J]. Immunol Rev, 2025, 329(1): e13409. DOI: 10.1111/imr.13409.
[27]	Zhao L, Pang Y, Zhou Y, et al. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade[J]. Signal Transduct Target Ther, 2024, 9(1): 142. DOI: 10.1038/s41392-024-01853-w.
[28]	Kleinendorst SC, Oosterwijk E, Bussink J, et al. Combining targeted radionuclide therapy and immune checkpoint inhibition for cancer treatment[J]. Clin Cancer Res, 2022, 28(17): 3652-3657. DOI: 10.1158/1078-0432.CCR-21-4332. pmid: 35471557
[29]	Verginadis II, Citrin DE, Ky B, et al. Radiotherapy toxicities: mechanisms, management, and future directions[J]. Lancet, 2025, 405(10475): 338-352. DOI: 10.1016/S0140-6736(24)02319-5. pmid: 39827884
[30]	文英美, 夏锦雄, 王园园, 等. 放疗对抗肿瘤免疫的影响: 从基础到临床[J]. 国际肿瘤学杂志, 2025, 52(4): 231-236. DOI: 10.3760/cma.j.cn371439-20240727-00038.
[31]	Youssef A, Sahgal A, Das S. Radioresistance and brain metastases: a review of the literature and applied perspective[J]. Front Oncol, 2024, 14: 1477448. DOI: 10.3389/fonc.2024.1477448.
[32]	Zhou T, Zhang LY, He JZ, et al. Review: mechanisms and perspective treatment of radioresistance in non-small cell lung cancer[J]. Front Immunol, 2023, 14: 1133899. DOI: 10.3389/fimmu.2023.1133899.
[33]	Kleinendorst SC, Oosterwijk E, Molkenboer-Kuenen J, et al. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma[J]. Theranostics, 2024, 14(9): 3693-3707. DOI: 10.7150/thno.96944. pmid: 38948062
[34]	Hébert K, Bodin-Cufi P, Fersing C, et al. New drugs for targeted radionuclide therapy in metastatic prostate cancer[J]. Eur Urol Focus, 2024, 10(4): 514-517. DOI: 10.1016/j.euf.2024.07.016. pmid: 39142998
[35]	Mourtada F, Tomiyoshi K, Sims-Mourtada J, et al. Actinium-225 targeted agents: where are we now?[J]. Brachytherapy, 2023, 22(6): 697-708. DOI: 10.1016/j.brachy.2023.06.228. pmid: 37690972
[36]	Wichmann CW, Morgan KA, Cao Z, et al. Radiolabeling and preclinical evaluation of therapeutic efficacy of ²²⁵Ac-ch806 in glioblastoma and colorectal cancer xenograft models[J]. J Nucl Med, 2024, 65(9): 1456-1462. DOI: 10.2967/jnumed.123.266894.
[37]	Królicki L, Bruchertseifer F, Kunikowska J, et al. Safety and efficacy of targeted alpha therapy with ²¹³Bi-DOTA-substance P in recurrent glioblastoma[J]. Eur J Nucl Med Mol Imaging, 2019, 46(3): 614-622. DOI: 10.1007/s00259-018-4225-7.
[38]	Królicki L, Kunikowska J, Bruchertseifer F, et al. Locoregional treatment of glioblastoma with targeted α therapy: [²¹³Bi] Bi-DOTA-substance P versus [²²⁵Ac] Ac-DOTA-substance P-analysis of influence parameters[J]. Clin Nucl Med, 2023, 48(5): 387-392. DOI: 10.1097/RLU.0000000000004608.
[39]	Flux G, Leek F, Gape P, et al. Iodine-131 and iodine-131-meta-iodobenzylguanidine dosimetry in cancer therapy[J]. Semin Nucl Med, 2022, 52(2): 167-177. DOI: 10.1053/j.semnuclmed.2021.11.002.
[40]	Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review[J]. JAMA, 2024, 331(5): 425-435. DOI: 10.1001/jama.2023.26348. pmid: 38319329
[41]	Sobral DV, Fuscaldi LL, Durante ACR, et al. Comparative evaluation of radiochemical and biological properties of ¹³¹I-and [^99mTc]Tc(CO)₃-labeled RGD analogues planned to interact with the α_vβ₃ integrin expressed in glioblastoma[J]. Pharmaceuticals (Basel), 2022, 15(2): 116. DOI: 10.3390/ph15020116.
[42]	Gao J, Fang L, Sun D, et al. ¹³¹I-labeled and DOX-loaded multifunctional nanoliposomes for radiotherapy and chemotherapy in brain gliomas[J]. Brain Res, 2020, 1739: 145218. DOI: 10.1016/j.brainres.2016.12.014.
[43]	Higashi Y, Ma Y, Matsumoto K, et al. Auger electrons and DNA double-strand breaks studied by using iodine-containing chemicals[J]. Enzymes, 2022, 51: 101-115. DOI: 10.1016/bs.enz.2022.08.007. pmid: 36336404
[44]	Madsen KL, Therkelsen ASN, Langkjær N, et al. Auger electron therapy of glioblastoma using [¹²⁵I]5-iodo-2'-deoxyuridine and concomitant chemotherapy-evaluation of a potential treatment strategy[J]. Nucl Med Biol, 2021, 96-97: 35-40. DOI: 10.1016/j.nucmedbio.2021.03.001.
[45]	Pirovano G, Jannetti SA, Carter LM, et al. Targeted brain tumor radiotherapy using an auger emitter[J]. Clin Cancer Res, 2020, 26(12): 2871-2881. DOI: 10.1158/1078-0432.CCR-19-2440. pmid: 32066626
[46]	Liu W, Ma H, Liang R, et al. Targeted alpha therapy of glioma using ²¹¹At-labeled heterodimeric peptide targeting both VEGFR and integrins[J]. Mol Pharm, 2022, 19(9): 3206-3216. DOI: 10.1021/acs.molpharmaceut.2c00349.
[47]	Jannetti SA, Carlucci G, Carney B, et al. PARP-1-targeted radiotherapy in mouse models of glioblastoma[J]. Journal of Nuclear Medicine, 2018, 59(8): 1225-1233. DOI: 10.2967/jnumed.117.205054.
[48]	Roncali L, Marionneau-Lambot S, Roy C, et al. Brain intratumoural astatine-211 radiotherapy targeting syndecan-1 leads to durable glioblastoma remission and immune memory in female mice[J]. EBioMedicine, 2024, 105: 105202. DOI: 10.1016/j.ebiom.2024.105202.
[49]	Lai C, Cao R, Li R, et al. Fibroblast activation protein targeting probe with Gly-Pro sequence for PET of glioblastoma[J]. Mol Pharm, 2023, 20(8): 4120-4128. DOI: 10.1021/acs.molpharmaceut.3c00248.
[50]	Ge W, Chen G, Huang X, et al. Heteroions radii matching produced intensely luminescent bismuth-Ag2S nanocrystals for through-skull NIR-Ⅱ imaging of orthotopic glioma[J]. Nano Lett, 2024, 24(15): 4562-4570. DOI: 10.1021/acs.nanolett.4c00604.
[51]	Ge MH, Zhu XH, Shao YM, et al. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer[J]. Biomater Sci, 2021, 9(4): 1313-1324. DOI: 10.1039/d0bm01832e.